Lentiviral Delivery

Lentiviral Delivery employs vectors derived from lentiviruses (typically HIV-1) to integrate transgenes into the genome of both dividing and non-dividing cells, providing stable, long-term expression ¹.

How It Works

Lentiviral vectors are produced by co-transfecting packaging cells with separate plasmids encoding the viral structural proteins (gag-pol), envelope glycoprotein (commonly VSV-G for broad tropism), and the transfer vector containing the transgene flanked by long terminal repeats (LTRs). Self-inactivating (SIN) designs delete enhancer elements from the 3’ LTR, reducing the risk of transcriptional activation of nearby genes after integration.

Unlike gammaretroviral vectors, lentiviruses can transduce non-dividing cells because their pre-integration complex actively traverses the nuclear pore. This property makes lentiviral vectors suitable for transducing neurons, hematopoietic stem cells, and other quiescent cell populations. Packaging capacity is approximately 8-10 kilobases, larger than AAV vectors.

Lentiviral vectors integrate semi-randomly with a preference for active transcription units. While this enables stable expression, it carries a risk of insertional mutagenesis. Modern SIN vector designs and insulator elements mitigate this risk. Lentiviral delivery is the backbone of CAR-T cell manufacturing, pooled CRISPR screening libraries, and several approved gene therapies for hemoglobinopathies and immunodeficiencies ².

Computational Considerations

Integration site analysis uses high-throughput sequencing to map insertion positions, quantify clonal contributions, and detect enrichment near oncogenes. Statistical frameworks assess whether integration patterns deviate from random and flag potential genotoxicity risks for therapeutic vector safety evaluation ¹.

---

Woolf Software builds computational tools for genome editing design and off-target prediction. Get in touch.